Literature DB >> 20165977

Risk of non-melanoma skin cancer in autoimmune hepatitis.

John Leung1, Lauren Dowling, Isi Obadan, James Davis, Peter A Bonis, Marshall M Kaplan, Darlene Casey, Kathleen Viveiros.   

Abstract

BACKGROUND: Most patients with autoimmune hepatitis (AIH) require long-term immunosuppressive therapy (IS). While it is well established that solid organ transplant recipients have a high risk of developing non-melanoma skin cancer (NMSC) as a result of immunosuppression, little is known about the risk of NMSC associated with IS in patients with AIH.
OBJECTIVES: The aim of this study is to determine the incidence and risk factors for NMSC in patients on IS for AIH.
METHODS: We reviewed the medical records of all patients with AIH seen at a tertiary care medical center between 1998 and 2008. We compared the incidence of NMSC to an age- and sex-matched control population and analyzed risk factors for NMSC.
RESULTS: A total of forty-five patients with AIH were identified. Twenty NMSC lesions were found in eight patients. Compared to the age and sex-matched general population, the risk of SCC and BCC were increased as quantified by elevated standardized incidence ratios (28.5 and 5.0, respectively). Patients who developed NMSC were on average 24 years older (78.4 vs. 54.2 years old, p < 0.0001) and had AIH diagnosed at a more advanced age (66.0 vs. 45.4 years old, p = 0.0003).
CONCLUSION: The risk of NMSC is significantly increased in patients with AIH on immunosuppression. Independent risk factors include current age and age at diagnosis of AIH.

Entities:  

Mesh:

Year:  2010        PMID: 20165977     DOI: 10.1007/s10620-010-1145-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Duration of immunosuppressive therapy in autoimmune hepatitis.

Authors:  S Kanzler; G Gerken; H Löhr; P R Galle; K H Meyer zum Büschenfelde; A W Lohse
Journal:  J Hepatol       Date:  2001-02       Impact factor: 25.083

2.  Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer.

Authors:  C C Otley
Journal:  Dermatol Surg       Date:  2000-07       Impact factor: 3.398

Review 3.  Autoimmune hepatitis.

Authors:  Edward L Krawitt
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

4.  De novo tumors after liver transplantation: a single-institution experience.

Authors:  Edmund Q Sanchez; Shigeru Marubashi; Ghapjoong Jung; Marlon F Levy; Robert M Goldstein; Ernesto P Molmenti; Carlos G Fasola; Thomas A Gonwa; Linda W Jennings; Barbara K Brooks; Goran B Klintmalm
Journal:  Liver Transpl       Date:  2002-03       Impact factor: 5.799

5.  Trends in cancer risk among people with AIDS in the United States 1980-2002.

Authors:  Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

6.  De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival.

Authors:  J Ignacio Herrero; María Lorenzo; Jorge Quiroga; Bruno Sangro; Fernando Pardo; Fernando Rotellar; Javier Alvarez-Cienfuegos; Jesús Prieto
Journal:  Liver Transpl       Date:  2005-01       Impact factor: 5.799

7.  Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo.

Authors:  Camile L Hexsel; Melody J Eide; Christine C Johnson; Richard Krajenta; Gordon Jacobsen; Iltefat Hamzavi; Henry W Lim
Journal:  J Am Acad Dermatol       Date:  2009-04-17       Impact factor: 11.527

8.  Azathioprine for long-term maintenance of remission in autoimmune hepatitis.

Authors:  P J Johnson; I G McFarlane; R Williams
Journal:  N Engl J Med       Date:  1995-10-12       Impact factor: 91.245

9.  Aggressive biologic behavior of basal- and squamous-cell cancers in patients with chronic lymphocytic leukemia or chronic lymphocytic lymphoma.

Authors:  V M Weimar; R I Ceilley; J A Goeken
Journal:  J Dermatol Surg Oncol       Date:  1979-08

10.  Azathioprine and UVA light generate mutagenic oxidative DNA damage.

Authors:  Peter O'Donovan; Conal M Perrett; Xiaohong Zhang; Beatriz Montaner; Yao-Zhong Xu; Catherine A Harwood; Jane M McGregor; Susan L Walker; Fumio Hanaoka; Peter Karran
Journal:  Science       Date:  2005-09-16       Impact factor: 47.728

View more
  4 in total

Review 1.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

2.  Cancer Risk in Patients With Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology.

Authors:  Rajani Sharma; Elizabeth C Verna; Tracey G Simon; Jonas Söderling; Hannes Hagström; Peter H R Green; Jonas F Ludvigsson
Journal:  Am J Epidemiol       Date:  2022-01-24       Impact factor: 4.897

Review 3.  Risk and Surveillance of Cancers in Primary Biliary Tract Disease.

Authors:  Valery Hrad; Yoftahe Abebe; Syed Haris Ali; Jared Velgersdyk; Mohammed Al Hallak; Mohamad Imam
Journal:  Gastroenterol Res Pract       Date:  2016-06-19       Impact factor: 2.260

Review 4.  Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review.

Authors:  Benedetta Terziroli Beretta-Piccoli; Pietro Invernizzi; M Eric Gershwin; Carlo Mainetti
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 10.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.